Filing Flows › AbCellera Biologics (ABCL) › Recalls, complaints & regulation
AbCellera Biologics (ABCL): clinical trials
AbCellera Biologics (ABCL) beyond its filings: 2 active clinical trials.
AbCellera Biologics' latest quarter
AbCellera Biologics, Q2 2026: revenue $4.0M (-76% year over year), net loss $55.4M, operating cash flow $25.9M. The chart follows the revenue to costs, profit and cash.
Questions
How many clinical trials does AbCellera Biologics have?
2 active studies on ClinicalTrials.gov, 0 in phase 3.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.